Corvia Medical closes $55 million funding round to complete confirmatory trial and pursue FDA approval of Corvia Atrial Shunt
TEWKSBURY, Mass., June 17, 2025 /CNW/ -- Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, today announced the successful closure of a $55 million funding round from the company's existing investment syndicate of Third Rock Ventures, General Catalyst Partners, AccelMed, Lumira Ventures, and two strategic investors.
The funds will be used to complete the ongoing RESPONDER-HF trial, a double-blinded, randomized, sham-controlled, confirmatory trial of the Corvia ® Atrial Shunt currently underway at more than 65 institutions on three continents. The study is expected to generate the final supportive clinical data required for FDA approval of the shunt as a breakthrough treatment for heart failure with preserved and mildly reduced ejection fraction (HFpEF/HFmrEF).
"We are profoundly grateful for the unwavering support of our longstanding investors as we advance toward FDA submission of the Corvia Atrial Shunt," said George Fazio, CEO of Corvia Medical. "Their commitment furthers our mission to bring this transformative heart failure treatment to millions of patients worldwide."
Paul LaViolette, Board Chair of Corvia Medical, added, "We firmly believe Corvia has the potential to fundamentally alter the landscape of heart failure treatment, and our investors share that vision. With these resources, we are well-equipped to drive the company through the approval process and introduce this groundbreaking therapy to the market."
About heart failure (HF) and the Corvia Atrial Shunt
More than 26 million people worldwide have HF, and the majority have HFpEF, making it the largest unmet clinical need in cardiovascular medicine. The Corvia Atrial Shunt is designed to reduce elevated left atrial pressure (LAP), the primary contributor to HF symptoms, by creating a passage between the left and right atria, reducing HF events and improving quality of life. The Corvia Atrial Shunt was granted Breakthrough Device designation by the FDA in 2019. For information regarding RESPONDER-HF study eligibility, please visit https://treatmyheartfailure.com.
Corvia Medical, Inc. is revolutionizing the treatment of heart failure through novel transcatheter cardiovascular devices. Founded in 2009 and headquartered in Tewksbury, MA, privately-held Corvia is dedicated to transforming the standard of care for heart failure treatment, enabling patients to reclaim their lives. Visit https://corviamedical.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
2 hours ago
- Globe and Mail
Influenza Pipeline Outlook 2025 – Clinical Trials, Treatment, ROA, Medication, MOA, Revenue Share, Companies by DelveInsight
The Influenza pipeline is experiencing unprecedented growth, driven by 120+ active players, breakthrough therapies, and recent FDA fast-track designations, signaling a transformative decade ahead in Influenza treatment. Influenza Pipeline Summary DelveInsight's Influenza Emerging Drugs report highlights innovative therapies advancing the treatment and prevention of influenza. Key candidates include Moderna's mRNA-1010, a Phase III vaccine encoding HA glycoproteins of WHO-recommended strains; SAB Biotherapeutics' SAB-176, a quadrivalent, broadly neutralizing polyclonal antibody for severe influenza; ENA Respiratory's INNA-051, an immunomodulatory intranasal spray in Phase IIa; Codagenix's CODA-VAX H1N1, a universal live-attenuated flu vaccine in Phase I; and AlloVir's ALVR106, an allogeneic, off-the-shelf VST therapy targeting multiple respiratory viruses. The report further analyzes over 120+ pipeline drugs across various clinical stages, including Phase III, II, I, preclinical, and discovery. It categorizes therapies by route of administration (oral, intravenous, intranasal, inhalation, subcutaneous, etc.), molecule type (antibodies, vaccines, peptides, proteins, immunotherapies, small molecules, stem cells), and product type (mono, combination, or both). Moderna currently leads the late-stage pipeline, showcasing the growing diversity and innovation in influenza treatment strategies. Key Takeaways from the Influenza Pipeline Report Influenza pipeline report depicts a robust space with 120+ active players working to develop 120+ pipeline therapies for Influenza treatment. In August 2025, AstraZeneca launches the first FDA-approved influenza vaccine available for self- or caregiver administration, providing a convenient, household-based option for seasonal flu vaccination. AstraZeneca launches FluMist Home, the first-of-its-kind, at-home delivery service for FLUMIST®(Influenza Vaccine Live, Intranasal). FLUMIST is the first and only seasonal influenza vaccine approved to be self-administered by adults 18 to 49 years of age or administered by a parent or caregiver to individuals 2-17 years of age. In July 2025, SK bioscience, a global innovative vaccine and biotech company dedicated to advancing human health from prevention to cure, announced that it has submitted an Investigational New Drug (IND) application to the Ministry of Food and Drug Safety (MFDS) for Phase 1/2 clinical trials of a new influenza vaccine candidate, 'NBP607B'. This candidate integrates an adjuvant into its existing cell-based influenza vaccine, 'SKYCellflu', to improve protective efficacy. SK bioscience previously applied adjuvant technology in its COVID-19 vaccine, 'SKYCovione', and now aims to extend this approach to influenza vaccines as part of its broader platform strategy. In July 2025, GSK plc (LSE/NYSE: GSK) today announced it has started shipping doses of its trivalent seasonal influenza vaccines to US healthcare providers and pharmacies in preparation for the 2025-26 flu season. This immediately follows a licensing and lot-release approval from the US Food and Drug Administration (FDA). Both FLULAVAL and FLUARIX will be available in a 0.5mL, single-dose, pre-filled syringe and are indicated for people six months and older. In March 2025, Sanofi announced today the immediate adoption of influenza strains selected by the US Food and Drug Administration (FDA) to advance the manufacturing and delivery of its vaccine portfolio for the 2025-26 flu season in the US. As the world leader in flu vaccines, Sanofi had already begun its annual production of vaccines to ensure that robust supply is ready for the coming season. Strains selected by the FDA match those already used in production by the company to help protect eligible patients against flu and its potentially severe complications. In December 2024:- ModernaTX, Inc.- A Phase 3, Randomized, Observer-Blind, Active-Control Study to Evaluate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (SARS-CoV-2 and Influenza) Vaccine in Healthy Adults ≥50 Years of Age. The purpose the study is to evaluate the immunogenicity, reactogenicity, and safety of mRNA-1083 in adults 50 years of age and older in participating countries (Japan, Taiwan, and South Korea). In November 2024:- DiaSorin Molecular LLC- The DiaSorin Molecular LIAISON® NES FLU A/B, RSV & COVID-19 real-time polymerase chain reaction (RT-PCR) assay is intended for use on the DiaSorin LIAISON® NES instrument for the in-vitro qualitative detection and differentiation of nucleic acid from influenza A, influenza B, RSV and SARS-CoV-2 virus from dry nasal swabs (NS) from human patients with signs and symptoms during the acute phase of respiratory tract infection in conjunction with clinical and epidemiological risk factors. In October 2024:- Pfizer- The purpose of this study is to learn about the safety and effects of the study vaccine for the possible prevention of influenza. Influenza is a disease that can spread easily from one person to another and cause body aches, fever, cough, and other symptoms. The study vaccine is called Pandemic Influenza modRNA (pdmFlu) Vaccine. The leading Influenza Companies such as Moderna, SAB Biotherapeutics, ENA Respiratory Pty Ltd, Codagenix, AlloVir, Osivax, CureVac AG, GlaxoSmithKline, Cocrystal Pharma Inc, Viriom, Emergent BioSolutions, Pfizer, Jiangxi Qingfeng Pharmaceutical Co. Ltd., Guangdong Raynovent Biotech Co., Ltd, FluGen Inc, BlueWillow Biologics, AVM Biotechnology LLC, Ansun Biopharma, Inc., Guangzhou Henovcom Bioscience, Sunshine Lake Pharma Co., Ltd., Emergex Vaccines, Vir Biotechnology, CSL Limited, Novavax, EMERGENT, Mitsubishi Chemical Group Corporation, Poolbeg Pharma, MYMETICS, CELLTRION INC., Avalia Immunotherapies, Meiji Holdings Co., Ltd., Clover Biopharmaceuticals, Airway Therapeutics, Inc., PrEP Biopharm, Ansun Biopharma, Cidara Therapeutics, Inc., and others. Promising Influenza Therapies such as OVX836 480µg, mRNA-1010, Oseltamivir, Baloxavir, and others. Stay ahead with the most recent pipeline outlook for Influenza. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Influenza Treatment Drugs Influenza Emerging Drugs · mRNA-1010 (Moderna): A Phase III vaccine targeting WHO-recommended influenza strains (A/H1N1, A/H3N2, B/Yamagata, B/Victoria). Encodes HA glycoproteins to generate broad protection against seasonal influenza. · SAB-176 (SAB Biotherapeutics): A quadrivalent polyclonal antibody therapy developed via DiversitAb™ platform. Designed to neutralize Type A and B influenza viruses, showing broad protection potential. Targeted for severe cases and high-risk groups like elderly and immunocompromised patients. · INNA-051 (ENA Respiratory): An intranasal immunomodulatory spray in Phase IIa trials. Intended for pre- and post-exposure prophylaxis of respiratory viral infections, with potential use across multiple viruses and at-risk populations. · CODA-VAX H1N1 (Codagenix): A live-attenuated universal flu vaccine in Phase I trials. Shows promise for multi-season protection by targeting conserved viral antigens and is being developed into a quadrivalent formulation. · ALVR106 (AlloVir): An allogeneic, off-the-shelf VST therapy in preclinical development. Targets RSV, influenza, PIV, and hMPV, with in vitro data showing strong antiviral activity and potential safety benefits. Explore groundbreaking therapies and clinical trials in the Influenza Pipeline. Access DelveInsight's detailed report now! @ New Influenza Drugs Key influenza Companies: The following are the leading companies in the influenza market. These companies collectively hold the largest market share and dictate industry trends. Influenza Pipeline Drugs by Route of Administration Influenza pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration Inhalation Inhalation/Intravenous/Oral Intranasal Intravenous • Intravenous/ Subcutaneous • NA • Oral • Oral/intranasal/subcutaneous • Parenteral • Subcutaneous Influenza Pipeline Drugs by Molecule Types Influenza Products have been categorized under various Molecule types such as • Antibody • Antisense oligonucleotides • Immunotherapy • Monoclonal antibody • Peptides • Protein • Recombinant protein • Small molecule • Stem Cell • Vaccine Unveil the future of Influenza Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Influenza Market Drivers and Barriers Scope of the Influenza Pipeline Report Coverage- Global Influenza Companies- Moderna, SAB Biotherapeutics, ENA Respiratory Pty Ltd, Codagenix, AlloVir, Osivax, CureVac AG, GlaxoSmithKline, Cocrystal Pharma Inc, Viriom, Emergent BioSolutions, Pfizer, Jiangxi Qingfeng Pharmaceutical Co. Ltd., Guangdong Raynovent Biotech Co., Ltd, FluGen Inc, BlueWillow Biologics, AVM Biotechnology LLC, Ansun Biopharma, Inc., Guangzhou Henovcom Bioscience, Sunshine Lake Pharma Co., Ltd., Emergex Vaccines, Vir Biotechnology, CSL Limited, Novavax, EMERGENT, Mitsubishi Chemical Group Corporation, Poolbeg Pharma, MYMETICS, CELLTRION INC., Avalia Immunotherapies, Meiji Holdings Co., Ltd., Clover Biopharmaceuticals, Airway Therapeutics, Inc., PrEP Biopharm, Ansun Biopharma, Cidara Therapeutics, Inc., and others. Influenza Therapies- OVX836 480µg, mRNA-1010, Oseltamivir, Baloxavir, and others Influenza Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Influenza Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Table of Content 1. Influenza Report Introduction 2. Influenza Executive Summary 3. Influenza Overview 4. Influenza- Analytical Perspective In-depth Commercial Assessment 5. Influenza Pipeline Therapeutics 6. Influenza Late Stage Products (Phase II/III) 7. Influenza Mid Stage Products (Phase II) 8. Influenza Early Stage Products (Phase I) 9. Influenza Preclinical Stage Products 10. Influenza Therapeutics Assessment 11. Influenza Inactive Products 12. Company-University Collaborations (Licensing/Partnering) Analysis 13. Influenza Key Companies 14. Influenza Key Products 15. Influenza Unmet Needs 16 . Influenza Market Drivers and Barriers 17. Influenza Future Perspectives and Conclusion 18. Influenza Analyst Views 19. Appendix 20. About DelveInsight About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Ankit Nigam Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Albany State: New York Country: United States Website:
Toronto Star
9 hours ago
- Toronto Star
Techmer PM Introduces HiFill® GF-PET Material System to Bridge Gap Between Low and High Temperature Tooling Requirements, Filling a Critical Need
CLINTON, Tenn., Aug. 21, 2025 (GLOBE NEWSWIRE) — Techmer PM, a materials innovation company delivering advanced composites for additive manufacturing, has announced the commercial release of HiFill® GF-PET, a glass-filled polyethylene terephthalate material system engineered for 3D printing intermediate-temperature autoclave tooling. Tailored for use up to 250°F (121°C), this material offers a cost-effective alternative that bridges the gap between low-temperature and high-temperature thermoplastic material systems. As industries push toward more efficient and scalable composite part production, manufacturers face limited material choices for tooling that must perform reliably under autoclave conditions without exceeding budget constraints. The HiFill GF-PET fills this gap, delivering thermal stability and dimensional accuracy at an accessible cost, making it ideal for intermediate temperature tooling applications needed in the marine, automotive, wind, and aerospace industries.
Globe and Mail
10 hours ago
- Globe and Mail
Nutriband (NASDAQ: NTRB): When Regulatory Momentum Meets Leadership Continuity
FDA grants Type C Meeting for AVERSA(TM) Fentanyl to discuss Chemistry, Manufacturing, and Controls pathway from IND submission through NDA approval and commercialization CEO Gareth Sheridan temporarily steps aside to pursue Irish Presidential nomination while Chairman Serguei Melnik assumes interim CEO role during critical development phase Strategic partnership with Kindeva combines proven FDA-approved fentanyl patch technology with Nutriband's proprietary abuse-deterrent platform targeting $80-200 million peak U.S. market opportunity The pharmaceutical development landscape presents a fundamental shift as regulatory frameworks evolve beyond traditional efficacy-first approaches. The most significant patient impact now comes from innovations that enhance safety profiles of existing therapeutic options, particularly in pain management where the balance between therapeutic benefit and abuse potential creates urgent medical need alongside substantial regulatory complexity. The opioid crisis has reshaped how regulators approach pain management solutions. The most promising opportunities exist at the intersection of proven therapeutic benefit and enhanced safety mechanisms, requiring both technological innovation and regulatory expertise to navigate complex approval… Read More>> About BioMedWire BioMedWire ('BMW') is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, BMW brings its clients unparalleled recognition and brand awareness. BMW is where breaking news, insightful content and actionable information converge. To receive SMS alerts from BioMedWire, 'Biotech' to 888-902-4192 (U.S. Mobile Phones Only) For more information, please visit Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: BioMedWire San Francisco, CA 415.949.5050 Office Editor@ BioMedWire is powered by IBN
